Empirical Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Empirical Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.3M	Buy	73,041 +6,818	+10%	+$201K	0.03%	248
2026 Q1	$1.64M	Buy	66,223 +8,673	+15%	+$207K	0.03%	274
2025 Q4	$1.34M	Buy	57,550 +5,394	+10%	+$120K	0.02%	293
2025 Q3	$1.03M	Buy	+52,156	New	+$1.07M	0.02%	323
2022 Q2	–	Sell	-24,534	Closed	-$203K	–	477
2022 Q1	$203K	Buy	24,534 +12,524	+104%	+$88.5K	0.01%	472
2021 Q4	$81K	Buy	+12,010	New	+$79K	﹤0.01%	509

Other funds holding CPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Empirical Wealth Management's CPRX Position: Q2 2026 in Review

Empirical Wealth Management increased its Catalyst Pharmaceutical (CPRX) stake by 10% in Q2 2026, buying an estimated $201K and bringing the position to 73,041 shares worth $2.3M. The position accounts for 0.03% of the portfolio, ranked #248.

Empirical Wealth Management first reported a position in CPRX in Q4 2021 and has held it in 6 quarters since. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Empirical Wealth Management held 73,041 shares of Catalyst Pharmaceutical worth $2.3M as of Q2 2026.
Empirical Wealth Management bought 6,818 Catalyst Pharmaceutical shares in Q2 2026, an estimated $201K.
Catalyst Pharmaceutical made up 0.03% of Empirical Wealth Management's portfolio in Q2 2026, its #248 holding.
Empirical Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2021 and has held it in 6 quarters since.
36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Empirical Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.